Longevity Lab Report · Public evidence card
Did glucosamine relieve knee pain in GAIT?
Assessed 2026-11-15 · Main study published 2006-02-23
This card contains the public evidence assessment only.
Conclusion
GAIT did not establish an overall pain benefit for glucosamine hydrochloride alone. Its exploratory combination-treatment subgroup is not proof that glucosamine alone works.
- Population and design
- 1,583 people with symptomatic knee osteoarthritis. Randomized, double-blind, five-group trial.
- Studied intervention
- Glucosamine hydrochloride, 1,500 mg daily; separate groups tested chondroitin, the combination, and celecoxib.
- Comparator
- Placebo; celecoxib was an active comparison.
- Measured outcome
- At least a 20% reduction in knee pain. Follow-up: 24 weeks.
- Observed result
- 64.0% responded to glucosamine versus 60.1% to placebo: a 3.9 percentage-point difference, P=0.30. The combination also did not significantly outperform placebo overall.
- Main limitations
- The moderate-to-severe pain subgroup finding concerned the combination, not glucosamine alone.
- Hydrochloride and sulfate preparations should not be treated as identical interventions.
Baseline evidence assessment, not a new study or a revised library grade. This card contains no personal responses and does not recommend treatment.
Sources
- GAIT (Clegg et al., 2006)
Main study · Published 2006-02-23 · Checked 2026-11-15 · DOI 10.1056/NEJMoa052771
Primary publication abstract and indexed results
- Glucosamine sulfate trial (Reginster et al., 2001)
Context · Published 2001-01-27 · Checked 2026-11-15 · PMID 11214126
Primary publication abstract and indexed results
Public card: https://longevitylabreport.com/research/glucosamine-gait/card
Full explainer, context and assessment history